Gilead Sciences, Inc. Announces 48-Week Data Evaluating Switching from Combivir(R) To Truvada(R) Among Virologically-Suppressed HIV Patients

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD - News) today announced 48-week data from a Phase III clinical trial evaluating virologically-suppressed patients with HIV who switched from treatment with twice-daily Combivir®